MX2016017405A - Compuestos derivados de 2-(3-piridinil)-1h-benzimidazol y medicamentos que los contienen. - Google Patents
Compuestos derivados de 2-(3-piridinil)-1h-benzimidazol y medicamentos que los contienen.Info
- Publication number
- MX2016017405A MX2016017405A MX2016017405A MX2016017405A MX2016017405A MX 2016017405 A MX2016017405 A MX 2016017405A MX 2016017405 A MX2016017405 A MX 2016017405A MX 2016017405 A MX2016017405 A MX 2016017405A MX 2016017405 A MX2016017405 A MX 2016017405A
- Authority
- MX
- Mexico
- Prior art keywords
- group
- atom
- halogen
- atoms
- hydrogen atom
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 2
- -1 2-(3-pyridinyl)-1h-benzimidazole derivative compound Chemical class 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 8
- 125000005843 halogen group Chemical group 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 abstract 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000006165 cyclic alkyl group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000002560 nitrile group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere a un compuesto representado por la fórmula general (I) o una sal del mismo, y a un medicamento que contiene una sal del compuesto (en la fórmula, R1 representa un átomo de hidrógeno o un radical CO2Ra; R2 representa un átomo de hidrógeno, un átomo de halógeno ó CO2Ra; R3 representa un átomo de hidrógeno o un radical hidroxialquilo de 1 a 10 átomos de carbono; R4 representa un átomo de hidrógeno, un radical hidroxi, o un radical alcoxi de 1 a 10 átomos de carbono; R5 representa un radical alquilo de cadena lineal de 1 a 5 átomos de carbono, en el cual los átomos de hidrógeno opcionalmente son sustituidos por átomos de halógeno, un radical alquilo cíclico de 3 a 5 átomos de carbono, en el cual los átomo de hidrógeno opcionalmente son sustituidos por átomos de halógeno, un radical hidroxialquilo de 1 a 5 átomos de carbono, o un radical o-, p- o m-halobencilo; A representa CH o un átomo de nitrógeno; X1 y X3 independientemente representan átomos de hidrógeno o átomos de halógeno; X2 representa un átomo de hidrógeno, un átomo de halógeno, o un radical nitrilo; por lo menos uno de entre X1, X2 y X3 representa un átomo de halógeno; y Ra independientemente representa un radical alquilo de 1 a 1' átomos de carbono).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014131934 | 2014-06-26 | ||
| PCT/JP2015/068431 WO2015199205A1 (ja) | 2014-06-26 | 2015-06-25 | ２－（３－ピリジニル）－１ｈ－ベンゾイミダゾール誘導体化合物、及び、これを含む医薬 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016017405A true MX2016017405A (es) | 2017-08-24 |
Family
ID=54938282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016017405A MX2016017405A (es) | 2014-06-26 | 2015-06-25 | Compuestos derivados de 2-(3-piridinil)-1h-benzimidazol y medicamentos que los contienen. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10189815B2 (es) |
| EP (1) | EP3162802B1 (es) |
| JP (1) | JP6636921B2 (es) |
| KR (1) | KR20170017871A (es) |
| CN (1) | CN106458995B (es) |
| AU (1) | AU2015281060B2 (es) |
| CA (1) | CA2953692A1 (es) |
| ES (1) | ES2821273T3 (es) |
| MX (1) | MX2016017405A (es) |
| SG (1) | SG11201610217YA (es) |
| WO (1) | WO2015199205A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017213247A1 (ja) * | 2016-06-10 | 2017-12-14 | 日本メジフィジックス株式会社 | 心疾患の非侵襲的画像診断剤 |
| CN110312704A (zh) * | 2017-03-07 | 2019-10-08 | 日本医事物理股份有限公司 | 放射性氟标记前体化合物及使用其的放射性氟标记化合物的制造方法 |
| US11318216B2 (en) | 2017-06-23 | 2022-05-03 | Nihon Medi-Physics Co., Ltd. | Method for producing radiohalogen-labeled compound and method for producing radiopharmaceutical |
| JP7054134B2 (ja) * | 2017-12-07 | 2022-04-13 | 国立大学法人京都大学 | ベンゾ［ｂ］カルバゾール化合物及びそれを用いたイメージング |
| CN111527079B (zh) * | 2017-12-28 | 2023-08-11 | 日本医事物理股份有限公司 | 2-[5-（咪唑-1-基甲基）吡啶-3-基]苯并咪唑衍生物化合物及包含其的药物 |
| JP2021130610A (ja) * | 2018-05-08 | 2021-09-09 | 日本メジフィジックス株式会社 | 心疾患の非侵襲的画像診断剤 |
| JP2021181404A (ja) * | 2018-08-23 | 2021-11-25 | 日本メジフィジックス株式会社 | 放射性フッ素標識化合物の標識前駆体化合物を含有する溶液 |
| TW202016096A (zh) * | 2018-10-24 | 2020-05-01 | 日商日本醫事物理股份有限公司 | 放射性氟元素標示前驅物化合物的鹽類 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8071785B2 (en) | 2006-06-09 | 2011-12-06 | Ge Healthcare Limited | Synthesis and evaluation of 18F-labelled-alkyl-1-[(1R)-1-phenylethyl]-1H-imidazole-5-carboxylate as a tracer for the quantification of β-11-hydroxylase enzyme in the adrenal glands |
| EP2394668A1 (en) | 2010-06-01 | 2011-12-14 | Julius-Maximilians-Universität Würzburg | PET radiopharmaceuticals for differential diagnosis between bilateral and unilateral conditions of primary hyperaldosteronism |
| EP2595482A4 (en) | 2010-07-21 | 2013-12-25 | Merck Sharp & Dohme | ALDOSTERONSYNTHASEHEMMER |
| JP2015110563A (ja) | 2013-11-08 | 2015-06-18 | 日本メジフィジックス株式会社 | アルドステロン合成酵素阻害剤 |
-
2015
- 2015-06-25 ES ES15811977T patent/ES2821273T3/es active Active
- 2015-06-25 WO PCT/JP2015/068431 patent/WO2015199205A1/ja not_active Ceased
- 2015-06-25 KR KR1020167028804A patent/KR20170017871A/ko not_active Withdrawn
- 2015-06-25 JP JP2016529669A patent/JP6636921B2/ja active Active
- 2015-06-25 CN CN201580032760.3A patent/CN106458995B/zh active Active
- 2015-06-25 AU AU2015281060A patent/AU2015281060B2/en not_active Ceased
- 2015-06-25 MX MX2016017405A patent/MX2016017405A/es unknown
- 2015-06-25 US US15/321,972 patent/US10189815B2/en active Active
- 2015-06-25 SG SG11201610217YA patent/SG11201610217YA/en unknown
- 2015-06-25 CA CA2953692A patent/CA2953692A1/en not_active Abandoned
- 2015-06-25 EP EP15811977.6A patent/EP3162802B1/en active Active
-
2018
- 2018-12-06 US US16/211,434 patent/US10358434B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3162802A1 (en) | 2017-05-03 |
| CN106458995A (zh) | 2017-02-22 |
| ES2821273T3 (es) | 2021-04-23 |
| CA2953692A1 (en) | 2015-12-30 |
| US20190169169A1 (en) | 2019-06-06 |
| AU2015281060B2 (en) | 2019-03-14 |
| SG11201610217YA (en) | 2017-01-27 |
| US10358434B2 (en) | 2019-07-23 |
| EP3162802A4 (en) | 2018-01-17 |
| CN106458995B (zh) | 2019-12-20 |
| US20170158668A1 (en) | 2017-06-08 |
| KR20170017871A (ko) | 2017-02-15 |
| WO2015199205A1 (ja) | 2015-12-30 |
| AU2015281060A1 (en) | 2017-01-05 |
| JPWO2015199205A1 (ja) | 2017-04-20 |
| JP6636921B2 (ja) | 2020-01-29 |
| EP3162802B1 (en) | 2020-08-19 |
| US10189815B2 (en) | 2019-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016017405A (es) | Compuestos derivados de 2-(3-piridinil)-1h-benzimidazol y medicamentos que los contienen. | |
| CY1120188T1 (el) | ΠΑΡΑΓΩΓΑ ΝΑΦΘΥΡΙΔΙΝΗΣ ΧΡΗΣΙΜΑ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ ΙΝΤΕΓΚΡΙΝΗΣ αvβ6 | |
| CY1120635T1 (el) | Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης | |
| MX2015010775A (es) | Benzoxazoles sustituidos y metodos para usarlos. | |
| CY1124537T1 (el) | Παραγωγο πυριδονης που εχει τετραϋδροπυρανυλ μεθυλ ομαδα | |
| PE20151752A1 (es) | Amidas heterociclicas como inhibidores de cinasas | |
| TN2015000175A1 (en) | Heteroaryl substituted pyridyl compounds useful as kinase modulators | |
| MA39749A (fr) | Dérivés de pipéridine-dione | |
| NZ732657A (en) | Picolinamides with fungicidal activity and other related compounds | |
| PH12015502031A1 (en) | Tetrahydropyrrolothiazine compounds | |
| NZ732810A (en) | Picolinamides and other compounds | |
| JO3261B1 (ar) | مشتق بيريدين أحادي الحلقة | |
| MX2015017156A (es) | Inhibidores de bace. | |
| PH12012501385A1 (en) | Piperazine compound having a pgds inhibitory effect | |
| CY1117688T1 (el) | Ενωσεις τετραϋδροπυρρολοθειαζινης | |
| CY1121626T1 (el) | Νεο παραγωγο υδροξαμικου οξεος ή αλας αυτου | |
| PH12018501181A1 (en) | Phenyl derivatives as cannabinoid receptor 2 agonists | |
| SG10201805896SA (en) | PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS | |
| MX2016017371A (es) | Sal de compuesto heterociclico sustituido con halogeno. | |
| MX394157B (es) | Derivado de dihidropirrolopirazol sustituido. | |
| ZA202101487B (en) | Novel compounds | |
| MX375386B (es) | Compuesto de feniltetrahidroisoquinolina sustituido con heteroarilo. | |
| MX2015016332A (es) | Inhibidores de alk biciclicos fusionados. | |
| MY185971A (en) | Pyranodipyridine compound | |
| MY193239A (en) | Novel b-lactamase inhibitors |